Lifesci Capital restated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Get Rating) in a research note released on Thursday morning, PriceTargets.com reports.
Pyxis Oncology Stock Down 4.5 %
Shares of PYXS stock opened at $1.39 on Thursday. The business's fifty day simple moving average is $1.65 and its 200-day simple moving average is $2.25. Pyxis Oncology has a 12-month low of $1.34 and a 12-month high of $12.38.
Get Pyxis Oncology alerts:Pyxis Oncology (NASDAQ:PYXS – Get Rating) last issued its quarterly earnings results on Tuesday, November 1st. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.09). As a group, research analysts forecast that Pyxis Oncology will post -3.64 earnings per share for the current year.
Hedge Funds Weigh In On Pyxis Oncology
A number of large investors have recently made changes to their positions in the business. Tang Capital Management LLC increased its position in shares of Pyxis Oncology by 2.4% during the third quarter. Tang Capital Management LLC now owns 1,411,569 shares of the company's stock worth $2,781,000 after purchasing an additional 32,489 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Pyxis Oncology by 8.0% in the 3rd quarter. Vanguard Group Inc. now owns 917,384 shares of the company's stock valued at $1,807,000 after acquiring an additional 68,304 shares during the period. Citadel Advisors LLC increased its position in shares of Pyxis Oncology by 0.6% in the 3rd quarter. Citadel Advisors LLC now owns 1,530,785 shares of the company's stock valued at $3,015,000 after acquiring an additional 9,849 shares during the period. Renaissance Technologies LLC increased its position in shares of Pyxis Oncology by 70.9% in the 3rd quarter. Renaissance Technologies LLC now owns 128,802 shares of the company's stock valued at $254,000 after acquiring an additional 53,431 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in shares of Pyxis Oncology by 414.2% in the 3rd quarter. Tower Research Capital LLC TRC now owns 15,736 shares of the company's stock valued at $31,000 after acquiring an additional 12,676 shares during the period. 71.59% of the stock is owned by institutional investors and hedge funds.Pyxis Oncology Company Profile
(Get Rating)
Pyxis Oncology, Inc, a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.
Read More
- Get a free copy of the StockNews.com research report on Pyxis Oncology (PYXS)
- Why CSL Ltd Stock Could Be Worth a Look
- MarketBeat: Week in Review 11/28 – 12/02
- Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.